Organogenesis (NASDAQ:ORGO) Issues Earnings Results

Key Points

• Organogenesis reported earnings of ($0.09) EPS for the quarter, missing analyst expectations by ($0.08), with revenues of $101.01 million versus estimates of $104.75 million.
• Despite the earnings miss, Cantor Fitzgerald increased its price target for Organogenesis from $7.00 to $9.00 and rated the stock "overweight."
• Insider Lori Freedman purchased 9,022 shares at $2.99 each, increasing her total holdings in the company by 1.08%.

Organogenesis (NASDAQ:ORGO - Get Free Report) issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08), Zacks reports. Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%. The business had revenue of $101.01 million for the quarter, compared to analysts' expectations of $104.75 million. Organogenesis updated its FY 2025 guidance to EPS.

Organogenesis Stock Performance

NASDAQ:ORGO traded down $0.21 during mid-day trading on Thursday, reaching $4.70. The stock had a trading volume of 472,993 shares, compared to its average volume of 767,381. The firm has a market capitalization of $596.24 million, a price-to-earnings ratio of -33.57 and a beta of 1.76. Organogenesis has a twelve month low of $2.45 and a twelve month high of $6.71. The business has a 50 day simple moving average of $4.13 and a 200 day simple moving average of $4.09.

Insider Buying and Selling

In other news, insider Lori Freedman acquired 9,022 shares of Organogenesis stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average price of $2.99 per share, for a total transaction of $26,975.78. Following the completion of the transaction, the insider directly owned 846,459 shares in the company, valued at approximately $2,530,912.41. This trade represents a 1.08% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 252,264 shares of company stock valued at $725,732 in the last three months. 33.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC acquired a new stake in shares of Organogenesis in the second quarter valued at about $24,804,000. Raymond James Financial Inc. lifted its stake in shares of Organogenesis by 5.7% in the second quarter. Raymond James Financial Inc. now owns 444,240 shares of the company's stock valued at $1,626,000 after purchasing an additional 23,919 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Organogenesis by 36.6% in the second quarter. Russell Investments Group Ltd. now owns 168,152 shares of the company's stock valued at $617,000 after purchasing an additional 45,021 shares during the period. American Century Companies Inc. lifted its stake in shares of Organogenesis by 25.6% in the second quarter. American Century Companies Inc. now owns 164,793 shares of the company's stock valued at $603,000 after purchasing an additional 33,573 shares during the period. Finally, Norges Bank acquired a new stake in shares of Organogenesis in the second quarter valued at about $238,000. Institutional investors and hedge funds own 49.57% of the company's stock.

Analyst Upgrades and Downgrades

ORGO has been the topic of several research reports. Cantor Fitzgerald raised their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. BTIG Research reaffirmed a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.